Sidley represented the underwriters in the upsized US$198.7 million initial public offering by Tyra Biosciences, Inc. (NASDAQ: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. BofA Securities, Jefferies and Cowen acted as joint book-running managers of the offering.
The Sidley team was led by Global Life Sciences partner Frank Rahmani (Palo Alto and San Francisco) and Capital Markets partner Sam Gandhi (New York), and associates Alex Csordas and Nithya Swaminathan (each New York). Other critical support was provided by Life Sciences Transactions partner Asher Rubin (Baltimore) and associate Alison Lehner (Baltimore); Employee Benefits and Executive Compensation partner Corey Perry (Chicago) and associate Richard Schneider (Chicago); FDA Regulatory partner Torrey Cope (Washington, D.C.) and associate Kelly Cho (Washington, D.C.); and Tax partner Rachel Kleinberg (Palo Alto) and associate Marianne Tassone (San Francisco).